Background:Intravenous (IV) loop diuretics are recommended to relieve vascular congestion in patients with acute decompensated heart failure (ADHF); however, initial dosing is often empirical. Strong evidence supporting individualized diuretic dosing in the emergency department (ED) is lacking. Objective: The purpose of this study was to compare the efficacy and safety of aggressive (≥2 daily home doses) and conservative (<2 daily home doses) initial doses of loop diuretic. Methods: This was a retrospective cohort study in adult patients presenting to the ED with ADHF at an academic medical center from Apri 2015 to September 2015. The primary outcome was time to transition from IV to oral diuretics. Results: A total of 91 patients were included (aggressive dosing, n = 44; conservative dosing, n = 47). Mean time to transition from IV to oral diuretics was 67.9 hours in the aggressive group compared with 88.1 hours in the conservative group (P = 0.049). Mean hospital length of stay (LOS) was 119.5 hours in the aggressive group versus 123.0 hours in the conservative group (P = 0.799). No differences were observed between the mean urine output (P = 0.829), change in body weight (P = 0.528), or serum creatinine (P = 0.135). Conclusion: Patients who received an aggressive initial diuretic dose in the ED had a significantly faster time to oral diuretic therapy without any significant differences in hospital LOS, urine output, change in body weight, and renal function when compared with conservative dosing.
Introduction
Heart failure affects an estimated 5.7 million adults in the United States with the prevalence projected to increase 46% by year 2030. 1 Acute decompensated heart failure (ADHF) is a leading cause for emergency department (ED) visits and hospital admissions in the United States. There are nearly 1 million ED visits yearly, which accounts for a high financial burden to the health care system. 2 The 2013 American College of Cardiology (ACC) Foundation/American Heart Association (AHA) guidelines provide insight to optimize care but only offer general guidance for initial treatment. 3 Current ED goals of therapy are to relieve congestion and achieve euvolemia while avoiding harm, specifically myocardial and renal injury. 4 The recommendation for ADHF patients hospitalized with congestion is treatment with intravenous (IV) loop diuretics to reduce morbidity. Patients already on loop diuretic therapy prior to admission should receive an initial parenteral dose greater than or equal to their chronic daily dose; however, this range allows for a wide variation in treatment doses.
Previous trials have evaluated the effects of varying doses of diuretics. The Diuretic Optimization Strategies Evaluation (DOSE) trial was a randomized, prospective study that compared high-intensity diuretics (total IV furosemide dose 2.5 times the total daily oral loop diuretic dose) with low-intensity diuretics (total IV furosemide dose equal to the total daily oral loop diuretic dose) in patients with ADHF. 5 Highintensity diuretics resulted in greater net fluid loss, weight loss, and relief from dyspnea, but they found no significant differences in patients' global assessment of symptoms. Because the window of enrollment in the trial was in the first 24 hours of presentation, the study does not assess the effect of initial diuretic dosing. Another trial, a single-site retrospective study, concluded that there may be benefit to higher dosing strategies on presentation to the ED. 6 Nonetheless, evidence is lacking regarding personalized initial diuretic dosing strategies relative to the home dose. Therefore, this investigation aims to evaluate whether an aggressive initial dose of loop diuretic in ADHF confers any benefit over conservative dosing.
Methods
A retrospective cohort study was conducted at an academic medical center to compare aggressive with conservative dosing. Aggressive dosing was defined as an initial dose greater than or equal to double the total daily dose (TDD), and conservative dosing as an initial dose less than double the TDD. The aggressive dosing definition in this study was chosen to be lower than that in the high-intensity definition in the DOSE trial because our study's TDD was consolidated into a single initial dose rather than divided twice daily. Also, dosing calculations using this cutoff could more easily be calculated, if applied in the future. Loop diuretic dose equivalences are listed in Table 1 . 7, 8 During the study period, there were no diuretic dose selection tools, references, or clinical decision support at our institution. All IV diuretic doses were administered as an IV bolus over 1 to 2 minutes except for furosemide doses greater than 80 mg and bumetanide doses greater than 2 mg, which were given as infusions over 60 minutes. Patients were identified using ICD-9 codes, with a primary diagnosis of ADHF (428.0 and all subcategories) and presenting to the ED from April 2015 through September 2015. This study was approved by the investigational review board at the academic medical center.
Inclusion criteria were age 18 years and older, primary diagnosis of ADHF, and prescription of a loop diuretic prior to admission (PTA). Exclusion criteria included unclear diagnosis of ADHF, noncompliance of home diuretic greater than 2 weeks (obtained from chart notes), serum creatinine greater than 3.0 mg/dL, length of stay (LOS) less than 24 hours, incomplete treatment (leaving against medical advice or transferring to another hospital to complete treatment), and discharge without switching to oral therapy. Unclear diagnosis was determined by assessing History and Physical notes for diagnosis, concern, or active treatment for similar presenting disorders (eg, pneumonia or chronic obstructive pulmonary disease exacerbations).
Baseline patient characteristics included age, gender, body weight, ACC/AHA stage, functional classification, left-ventricular ejection fraction, mean arterial pressure, sodium, troponin, brain natriuretic peptide, serum creatinine, sequential organ failure assessment (SOFA) score, and receipt of diuretic or cardiovascular infusion during hospitalization. 9 The primary efficacy outcome was the time to transition from IV to oral diuretics. This outcome was the calculated time difference from the first IV dose to the first oral dose using the medication administration record. Secondary outcomes included hospital LOS, change in body weight over 24 hours after the initial dose, and urine output over 12 hours after the initial dose. Change in serum creatinine over 24 hours from baseline was evaluated for safety. Acute kidney injury (AKI) was defined as a 0.3-mg/ dL increase in serum creatinine over 24 hours. 10 Descriptive statistics were used to analyze demographic data. Continuous demographic data were presented as means and SDs for normally distributed data and medians and interquartile ranges for skewed data. Normality of variables was assessed by visualization of the data via histograms and residual analysis. Categorical demographic data were presented as numbers and percentages. Comparison of baseline characteristics, efficacy outcomes, and safety outcomes was assessed using a 2-sample t-test, Mann-Whitney U test, χ 2 test, or Fisher's exact test as appropriate. Correlation was used to describe the relationship between the time to transition from IV to oral diuretics and hospital LOS. P values <0.05 were considered statistically significant. Analyses were performed using SAS v9.4 (SAS Institute, Inc, Cary, NC) and Excel v15.18 (Microsoft, Redmond, WA).
Results
A total of 91 patients were included in this study (aggressive dosing, n = 44; conservative dosing, n = 47); see Figure 1 for details regarding screening and exclusion of patients. Baseline characteristics are shown in Table 2 . The majority of patients were elderly and had current symptoms of heart failure associated with underlying structural heart disease, with marked limitation of physical activity. Patients with both reduced and preserved ejection fraction were represented in this population. The baseline characteristics of the aggressive dosing and conservative dosing groups were statistically similar, with the exception of baseline serum creatinine (1.1 vs 1.3 mg/dL; P = 0.022) and median home TDD (40 vs 80 mg; P = 0.001). Also, the aggressive dosing group was more likely to have a once-daily home regimen (90.1% vs 21.3%; P = 0.001). In the conservative dosing group, 26 (55.3%) patients received an initial IV dose equal to their home TDD, whereas 17 (36.2%) patients received a dose lower than their TDD. In the aggressive dosing group, 32 (72.7%) patients received double their home TDD, whereas a relatively small number of patients received 4-fold their TDD (n = 11), and only 1 patient received 8-fold their TDD. Mean time to transition from IV to oral diuretics was 67.9 hours in the aggressive dosing group compared with 88.1 hours in the conservative dosing group (mean difference = 20.2 hours; P = 0.049); see Table 3 . Mean hospital LOS was 119.5 hours in the aggressive group versus 123.0 hours in the conservative group (P = 0.799). In the first 12 hours after the initial IV diuretic dose was given, mean urine output was similar between aggressive and conservative dosing (1783 vs 1730 mL, respectively; P = 0.829). There was no difference in change in body weight in the first 24 hours after the initial IV diuretic dose: −2.4 kg in the aggressive group versus −2.1 kg in the conservative group (P = 0.528).
Serum creatinine change from baseline to 24 hours was no different between both groups: −0.01 mg/dL in the aggressive group versus 0.04 mg/dL in the conservative group (P = 0.135); see Table 3 . Overall, AKI occurred in 4 patients (9.1%) in the aggressive group and 5 patients (10.6%) in the conservative group. Two patients in the aggressive dosing group who developed AKI received an initial dose 4 times greater than their PTA TDD, whereas 2 patients in the conservative group who developed AKI received an initial dose less than their PTA TDD.
There was a positive correlation between the time to transition from IV to oral diuretics and hospital LOS (r = 0.75; P < 0.001; n = 91). Approximately 56% of the variability in hospital LOS can be explained by the time of transition from IV to oral diuretics; see Figure 2 .
Discussion
This retrospective study contributes to the body of evidence that shows that it may be beneficial to individualize the initial single dose of loop diuretic in patients presenting to the ED with an ADHF exacerbation. These findings align with previous studies showing that higher dosing strategies in ADHF show benefit despite assessing different primary outcomes. 5, 6 However, we did not observe any difference in hospital LOS, which contradicts the results of FearonClarke et al. 6 Although the literature does not pinpoint a specific individualized initial diuretic dose to administer when patients present to the ED for an ADHF exacerbation, this study may help narrow the broad dosing range. The aggressive dosing group consisted of patients receiving doses of 2-, 4-, and 8-fold their chronic home TDD. Because the majority of patients received a 2-fold dose, the applicability of our results may be limited to this dose. The safety of 4-fold and 8-fold dosing should be interpreted with caution based on our low sample size in these subgroups. Administering higher doses of loop diuretics may increase the risk of ototoxicity and electrolyte imbalances, so intermittent infusions, instead of bolus administrations, may be warranted to mitigate these adverse effects. 11 To detail the 8-fold dose scenario, the patient received a furosemide initial IV dose of 40 mg and was on a home oral regimen of 10 mg daily.
To our knowledge, this is the first study in heart failure patients evaluating the impact of the initial dose in the ED on time to transition from IV to oral diuretics. This marker was chosen as a surrogate for resolution of ADHF exacerbation and was appropriate in a retrospective analysis given the multitude of confounding factors that may affect hospital LOS, such as complications during hospitalization, disposition issues, and other medical problems. In addition, transition to an oral diuretic is a retrospective signal that clinicians are no longer concerned about congestion and gastrointestinal edema affecting bioavailability of the diuretics. However, this marker may be affected by prescriber preference, and individual prescribers were not evaluated. To account for this possible confounding variable, the number of patients managed by a cardiology service was evaluated, and no difference was observed between both groups. The observed lack of benefit in urine output and change in body weight may have been a result of other unmeasured variables, such as documentation or recording inaccuracies, which are inevitable with retrospective design. In addition, the effect of maintenance dosing on these outcomes was not assessed. We hypothesize that starting an aggressive dose up front more likely leads to higher maintenance doses, which may possibly explain a difference in our primary outcome without changes in other short-term (12-and 24-hour) secondary outcomes. One difference between both the aggressive and conservative groups at baseline was the serum creatinine. Patients with moderate to severe renal dysfunction may have a blunted effect of diuretics, which may require higher diuretic doses to achieve the same effect. 3 This puts the conservative group at a disadvantage for a more rapid resolution of the exacerbation. However, this effect was not seen in this study, given the lack of difference in the urine output over 12 hours after the initial dose. The difference in baseline serum creatinine could be explained by provider prescribing. Some physicians may be more hesitant to give a relatively high dose of initial diuretic, with the thought that this may acutely worsen kidney function. On the contrary, reduction of fluid overload and venous congestion may improve volume status and thereby improve renal function. 12 Given no difference in mean arterial pressure between both groups, concern for hypotension as a confounding variable was unlikely.
Other differences between both groups included the home median dose and the home dosing regimen. Given the lack of standardized dosing guidance to prescribers at our institution, we expected a higher median dose in the conservative group by the nature of classifying conservative dosing as a ratio using home TDD as the denominator. We speculate that patients with a higher diuretic requirement at baseline, correlating with diuretic resistance, may require longer IV treatment throughout their hospital course, which puts the conservative group at a disadvantage. Furthermore, patients who have a higher TDD are more likely to have them split into multiple doses, accounting for the higher frequency of twice-daily regimens in the conservative group. Although not assessed in this study, we would expect a more robust initial dose response in patients with home twice-daily dosing compared with once-daily dosing because those patients would receive a higher initial dose relative to their incremental dose.
During data analysis, we identified 2 patients in the conservative group who were not representative of our population. The times to transition from IV to oral diuretics and hospital LOS for these 2 patients were greater than 5 SDs beyond the means. Clinically, they presented with a greater than 50-kg weight gain from baseline and ultimately had net fluid losses of 65 and 70 L on discharge. These 2 patients were excluded because they biased the data to falsely show a greater difference in the primary outcome.
Limitations
Limitations of this study include those inherent with a retrospective study design and the use of time to transition from IV to oral diuretics as a surrogate marker for resolution of ADHF exacerbation. The scope of this study was limited to initial dosing, but the primary outcome and LOS may be affected by changes in magnitude and frequency of subsequent diuretic dosing that continue beyond the initial dose. 5 This study serves as a bridge to future prospective trials to identify the optimal individualized initial diuretic dose.
Conclusion
In this small study, patients who received an aggressive initial diuretic dose, defined as greater than or equal to double their chronic home TDD, in the ED had a significantly faster transition to oral diuretic therapy without marked effects on urine output, change in body weight, and renal function when compared with conservative dosing. Despite a modest correlation between the time to transition to oral diuretics and hospital LOS, no significant difference in LOS was observed between aggressive and conservative initial IV diuretic doses. Nonetheless, future prospective studies are needed to confirm these findings and identify the optimal individualized diuretic dose.
